読み込み中
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.
前日終値
$1.26
+$0.01 · +0.80%
日中の時刻はETです。市場データは遅延する場合があります。
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.
日中レンジ
現在 $1.26
52週レンジ
現在 $1.26
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
81
大幅な割安
センチメント
55
まちまち
リスク
85
極めて高いリスク
モメンタム
22
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.
日中レンジ
現在 $1.26
52週レンジ
現在 $1.26
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 7294.9万 USD | 4150.6万 USD | 75.5万 USD | 1917.1万 USD | 3034.6万 USD |
| 売上原価 | 979.7万 USD | 918.2万 USD | 741.9万 USD | 848.4万 USD | 184.4万 USD |
| 粗利益 | 6315.2万 USD | 3232.4万 USD | −666.4万 USD | 1068.7万 USD | 2850.2万 USD |
| 研究開発 | 9351.7万 USD | 9053.6万 USD | 8764.6万 USD | 9750.1万 USD | 1.18億 USD |
| 販売・一般管理 | 859.6万 USD | 842万 USD | 811.9万 USD | 889.5万 USD | 2288.2万 USD |
| 営業費用 | 9622.8万 USD | 9187.8万 USD | 9063.8万 USD | 1億 USD | 1.32億 USD |
| 受取利息 | 949.8万 USD | 1127.8万 USD | 361.4万 USD | 112万 USD | 71.9万 USD |
| 支払利息 | 810.7万 USD | 745.3万 USD | 530.7万 USD | 378.7万 USD | 417.1万 USD |
| 減価償却費と償却費 | 2006.2万 USD | 1984.6万 USD | 1852.3万 USD | 1843.5万 USD | 1415.6万 USD |
| 営業利益 | −3307.6万 USD | −5955.4万 USD | −9730.2万 USD | −8966.6万 USD | −1.03億 USD |
| 純利益 | −6759.3万 USD | −3676.1万 USD | −1.01億 USD | −1.06億 USD | −1.14億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$2.15
上昇余地（70.63%）この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
